Phreesia, Inc. $PHR Shares Sold by Voya Investment Management LLC

Key Points

• Voya Investment Management LLC has reduced its stake in Phreesia, Inc. by 18.2% in the first quarter, now owning about 0.22% of the company, valued at approximately $3.3 million.
• Phreesia reported a quarterly earnings per share of $0.01, which beat analysts' expectations, alongside a revenue increase of 14.9% compared to the previous year.
• Multiple analysts have increased their price targets for Phreesia, with Canaccord Genuity recently setting a target of $38.00 and the stock receiving a Buy consensus rating.

Voya Investment Management LLC reduced its position in Phreesia, Inc. (NYSE:PHR - Free Report) by 18.2% in the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 130,223 shares of the company's stock after selling 29,051 shares during the quarter. Voya Investment Management LLC owned about 0.22% of Phreesia worth $3,328,000 at the end of the most recent reporting period.

Several other large investors have also modified their holdings of PHR. Ameriprise Financial Inc. acquired a new stake in shares of Phreesia in the fourth quarter valued at approximately $269,000. BNP Paribas Financial Markets acquired a new stake in shares of Phreesia in the fourth quarter valued at approximately $163,000. Deutsche Bank AG raised its stake in shares of Phreesia by 95.9% during the fourth quarter. Deutsche Bank AG now owns 57,297 shares of the company's stock worth $1,442,000 after purchasing an additional 28,047 shares during the last quarter. Nuveen Asset Management LLC raised its stake in shares of Phreesia by 77.1% during the fourth quarter. Nuveen Asset Management LLC now owns 235,827 shares of the company's stock worth $5,933,000 after purchasing an additional 102,662 shares during the last quarter. Finally, ProShare Advisors LLC raised its stake in shares of Phreesia by 49.0% during the fourth quarter. ProShare Advisors LLC now owns 15,585 shares of the company's stock worth $392,000 after purchasing an additional 5,127 shares during the last quarter. 92.10% of the stock is owned by institutional investors and hedge funds.

Phreesia Stock Down 1.3%

PHR opened at $23.87 on Friday. The company has a quick ratio of 2.12, a current ratio of 2.12 and a debt-to-equity ratio of 0.02. The firm has a market cap of $1.43 billion, a P/E ratio of -56.83 and a beta of 0.72. Phreesia, Inc. has a 52 week low of $17.07 and a 52 week high of $32.76. The business's fifty day simple moving average is $27.57 and its 200 day simple moving average is $26.38.

Phreesia (NYSE:PHR - Get Free Report) last posted its quarterly earnings data on Thursday, September 4th. The company reported $0.01 EPS for the quarter, beating analysts' consensus estimates of ($0.07) by $0.08. The business had revenue of $117.26 million for the quarter, compared to analyst estimates of $116.39 million. Phreesia had a negative return on equity of 8.75% and a negative net margin of 5.35%.The business's revenue for the quarter was up 14.9% compared to the same quarter last year. During the same quarter last year, the company earned ($0.03) earnings per share. Phreesia has set its FY 2026 guidance at EPS. As a group, equities research analysts anticipate that Phreesia, Inc. will post -1.1 EPS for the current fiscal year.

Insider Transactions at Phreesia

In other Phreesia news, SVP Amy Beth Vanduyn sold 1,762 shares of the firm's stock in a transaction dated Tuesday, September 16th. The stock was sold at an average price of $23.28, for a total value of $41,019.36. Following the sale, the senior vice president directly owned 112,479 shares of the company's stock, valued at approximately $2,618,511.12. This trade represents a 1.54% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Evan Roberts sold 3,761 shares of the firm's stock in a transaction dated Tuesday, September 16th. The stock was sold at an average price of $23.28, for a total value of $87,556.08. Following the completion of the sale, the insider directly owned 726,837 shares in the company, valued at approximately $16,920,765.36. The trade was a 0.51% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 128,250 shares of company stock worth $3,737,117 in the last quarter. 5.50% of the stock is currently owned by corporate insiders.

Wall Street Analyst Weigh In

Several equities research analysts have recently commented on the company. Canaccord Genuity Group upped their price target on Phreesia from $34.00 to $38.00 and gave the stock a "buy" rating in a research note on Friday, September 5th. Needham & Company LLC upped their price target on Phreesia from $29.00 to $35.00 and gave the stock a "buy" rating in a research note on Friday, September 5th. JMP Securities upped their price target on Phreesia from $30.00 to $34.00 and gave the stock a "market outperform" rating in a research note on Monday, September 8th. KeyCorp upped their price target on Phreesia from $28.00 to $35.00 and gave the stock an "overweight" rating in a research note on Monday, July 14th. Finally, Mizuho assumed coverage on Phreesia in a research note on Wednesday, August 27th. They set an "outperform" rating and a $36.00 price target for the company. One equities research analyst has rated the stock with a Strong Buy rating and twelve have given a Buy rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of "Buy" and an average target price of $34.08.

About Phreesia

Phreesia, Inc provides an integrated SaaS-based software and payment platform for the healthcare industry in the United States and Canada. The company offers access solutions that offers appointment scheduling system for online appointments, reminders, and referral tracking management; registration solution to automate patient self-registration; revenue cycle solution, which offer insurance-verification processes, point-of-sale payments applications, post-visit payment collection, and flexible payment options; and network connect solution to deliver clinically relevant content to patients.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.